Karyopharm Therapeutics | KPTI - 贷款资金



金融业
股票价格
USD
资产
USD 131.42M
现金及等价物
USD 90.85M
销售成本
USD 1.35M
流动资产
USD 126.33M
流动负债
USD 117.3M
债务
USD 299.23M
股息收益率
0
EBIT
USD -26.76M
EBITDA
USD -26.2M
员工
325
EPS每股收益
USD -1.02
股本和储备
USD -265.65M
销售毛利
USD 33.72M
债务利息支出
USD 12.55M
利息收入
USD -0.15
贷款资金
USD 264.49M
市值
USD 230.7M
净收入
USD -22.39M
营业费用
USD 61.83M
营业利润
USD -26.76M
普通股股本
USD 22.54M
税前利润
USD -22.39M
销售收入
USD 35.07M
销售和管理费用
USD 10.42M
股票
USD 4.04M
贸易债权人
USD 4.28M
应收帐款人
USD 23.36M


贷款资金 更改 日
AbbVie USD 64.53B 5.59B 2026-03
Abbott USD 29.64B 19.74B 2026-03
Amgen USD 51.86B 27M 2026-06
AstraZeneca USD 26.01B 46M 2026-06
BioCryst Pharmaceuticals USD 395.4M 203K 2026-06
Bristol-Myers Squibb USD 42.09B 59M 2026-06
Eli Lilly USD 47.86B 8.49B 2026-06
Enanta Pharmaceuticals USD 0 0 2024-12
GlaxoSmithKline GBP 13.95B 65M 2026-06
Incyte USD 28.42M 994K 2026-06
J&J USD 37.34B 183M 2026-06
Karyopharm Therapeutics USD 264.49M 13.73M 2026-03
MacroGenics USD 68.71M 1.29M 2026-03
Merck USD 51.08B 4.41B 2026-06
Nektar Therapeutics USD 60.27M 2.89M 2026-03
Novartis USD 37.49B 42M 2026-06
Novartis USD 37.45B 7.86B 2026-03
Pfizer USD 60.5B 70M 2026-06
Regeneron Pharmaceuticals USD 1.99B 400K 2026-06
Roche Holding CHF 25.22B 2.21B 2026-06
Sangamo BioSciences USD 0 0 2022-06
Takeda JPY 4.42T 50.32B 2026-06
Tectonic Therapeutic USD 17K 26K 2026-03
TG Therapeutics USD 745.39M 247K 2026-06
Ultragenyx Pharmaceutical USD 1.13B 19M 2026-03
Xencor USD 77.54M 4.59M 2026-06